1st Quarter - Amendment

RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION

Firm
Client
Income
—
Expenses
$60,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

HR 4758 - Accelerating Kids Access to Care Act

LobbyistCovered position, as disclosed
YOKO ROSENBAUM —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 4758 (119th)

Pharmacy PHA

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7384 (119th), H.R. 1262 (119th), H.R. 1414 (119th), H.R. 946 (119th)

Science/Technology SCI

HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 1532 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.